Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update

Go back to Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update
Goss & De Leeuw Mach Co (NASDAQ: GOSS) Delayed: 11.28 --0 (-0%)
Previous Close $11.28    52 Week High $0.00 
Open $11.28    52 Week Low $0.00 
Day High $11.28    P/E N/A 
Day Low $11.28    EPS $0.00 
Volume 623